Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal
Brian Dean
DOI: https://doi.org/10.1080/13543784.2023.2288074
2023-12-01
Expert Opinion on Investigational Drugs
Abstract:Introduction Successful phase 3 trials of KarXT in people with schizophrenia herald a new era of treating the disorder with drugs that do not target the dopamine D2 receptor. The active component of KarXT is xanomeline, a muscarinic (CHRM) M1 and M4 agonist, making muscarinic receptors a viable target for treating schizophrenia.
pharmacology & pharmacy
What problem does this paper attempt to address?